CoreValve Names Vito A. Canuso III
as Vice President, Intellectual Property
IRVINE, Calif. (Business Wire EON/PRWEB ) May 2, 2008 --
CoreValve (www.corevalve.com)
announced today that it has appointed Vito A. Canuso III as Vice
President, Intellectual property. In this position, Mr. Canuso’s
immediate focus will include managing the worldwide patent litigation
with Edwards Lifesciences. He also will assume responsibilities for
expanding CoreValve’s global patent portfolio
and for developing IP strategies that are intended to enhance CoreValve’s
growing leadership position in the transcatheter heart valve therapy
market.
Mr. Canuso joins CoreValve from one of the largest intellectual property
law firms in the United States—Knobbe,
Martens, Olson & Bear (KMOB), LLP—where
he has been a Partner since 1995, as well as a senior member of the firm’s
IP Litigation Department and its Patent Prosecution Department. Mr.
Canuso is registered to practice before the U.S. Patent and Trademark
office and a member of the State Bar of California. He received his law
degree in 1990 from the University of San Diego. Additionally, he holds
a bachelor’s degree in mechanical engineering
from Villanova University and a master’s
degree in civil engineering from the University of Notre Dame.
“Vito Canuso has litigated cases before
numerous district courts across the U.S. and has handled and argued
appeals to the Federal Circuit Court of Appeals. Additionally, he has
tried a case before the International Trade Court in Washington, D.C.,”
said Jacques Séguin, M.D., Ph.D., Chairman
and Founder of CoreValve. “Certainly, his
significant experience and proven medical specialty device expertise are
expected to serve CoreValve well as the Company asserts its intellectual
property and legal rights relating to its proprietary ReValving®
System for transcatheter aortic valve replacement in high-risk
patients.”
About CoreValve
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving®
System allows both percutaneous aortic valve replacement (PAVR)
and transapical aortic valve replacement (TAVR) and is intended
to provide an alternative to open-heart surgery. The ReValving®
System procedures are performed on the beating heart without cardiac
assistance or rapid pacing, and may result in less trauma to the
patient. This technology may also offer substantial cost-savings to the
healthcare system. The catheter-based technology includes a proprietary
framed/self-expanding tissue heart valve that is specifically designed
and engineered for transcatheter delivery. For more information about
CoreValve, visit the Company’s Web site at www.corevalve.com.
(Caution: the CoreValve ReValving®
System will not be available in the USA for clinical trials or for sale
until further notice.)
See the original story at: http://eon.businesswire.com/releases/corevalve/canuso/prweb912704.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1TcXVhLUZhbHUtQ3Jhcy1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
